Mutated genes in pancreatic cancer

Chinese Journal of Cancer Research

Volumn 22, Issue 2, 2010, Pages 93-98

  He, Song Bing ^a   Li, De Chun ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Epithelial growth factor; Matrix metalloproteinases; Oncogenes; Pancreatic cancer

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; K RAS PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN;

ADVANCED CANCER; CANCER SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; REVIEW;

EID: 77954663397     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-010-0093-9     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin 2008; 58: 71-96.
2. Li D, Xie K, Wolff R, et al. Pancreatic cancer[J]. Lancet 2004; 363: 1049-1057
3. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer[J]. Br J Surg 2004; 91: 1410-1427
4. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice[J]. Gastroenterology 2005; 128: 1626-1641
5. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial[J]. JAMA 2007; 297: 267-277
6. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med 2004; 350: 1200-1210
7. Pasca di Magliano M, Sekine S, Ermilov A, et al. Hedgehog/Ras interactions regulate early stages of pancreatic cancer[J]. Genes Dev 2006; 20: 3161-3173
8. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis[J]. Am J Clin Pathol 2002; 117: 755-765
9. Rozenblum E, Schutte M, Goggins M, et al. Tumorsuppressive pathways in pancreatic carcinoma[J]. Cancer Res 1997; 57: 1731-1734
10. Ren XY, Liang ZY, Shi XH, et al. A homologous promoterless K-ras CDNA targeting endogenous K-ras expression inhibits human pancreatic cancer cell growth in vitro and in vivo[J]. Cancer Biol Ther 2008; 7: 1641-1647
11. Brunner TB, Cengel KA, Hahn SM, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras[J]. Cancer Res 2005; 65: 8433-8441
12. Kawesha A, Ghaneh P, Andren Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adeno- carcinoma[J]. Int J Cancer 2000; 89: 469-474
13. Dong M, Ma G, Tu W, et al. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer[J]. World J Gastroenterol 2005; 11: 2162-2165 (Pubitemid 40542663)
14. Casneuf VF, Fonteyne P, Van Damme N, et al. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival[J]. Cancer Invest 2008; 26: 852-859
15. Sun Y. p53 and its downstream proteins as molecular targets of cancer[J]. Mol Carcinog 2006; 45: 409-415
16. Sui X, Shin S, Zhang R, et al. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells[J]. Oncogene 2009; 28: 709-720
17. Dong M, Dong Q, Zhang H, et al. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes[J]. J Surg Oncol 2007; 95: 332-336 (Pubitemid 46355510)
18. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas[J]. Cancer Res 1997; 57: 3126-3130
19. Hu YX, Watanabe H, Ohtsubo K, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma[J]. Clin Cancer Res 1997; 3: 1473-1477
20. Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation[J]. Ann Surg Oncol 2009; 16: 431-439
21. Schulz P, Scholz A, Rexin A, et al. Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis[J]. Br J Cancer 2008; 99: 110-117
22. Blobe GC, Schiemann WP, Lodish HF, et al. Role of transforming growth factor beta in human disease[J]. N Engl J Med 2000; 342: 1350-1358
23. Wilentz RE, Iacobuzio Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression[J]. Cancer Res 2000; 60: 2002-2006.
24. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma[ J]. Clin Cancer Res 2001; 7: 4115-4121
25. Cao D, Ashfaq R, Goggins MG, et al. Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in pancreatic cancer[J]. Int J Clin Exp Pathol 2008; 1: 510-517
26. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol 2009; 27: 1806-1813
27. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer[J]. Clin Cancer Res 2009; 15: 4674-4679
28. Khorana AA, Hu YC, Ryan CK, et al. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer[J]. J Gastrointest Surg 2005; 9: 903-911
29. Talar-Wojnarowska R, Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarci- noma: potential clinical implications[J]. Med Sci Monit 2006; 12: 186-193
30. Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis[J]. JOP 2006; 7: 283-294
31. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer[J]. Semin Oncol 2002; 29(suppl 14): 31-37
32. Muslimov GF. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma [J]. Bull Exp Biol Med 2008; 145: 535-538
33. Tzeng CW, Frolov A, Frolova N, et al. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients[J]. J Surg Res 2007; 143: 20-26
34. Azzariti A, Porcelli L, Gatti G, et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors on pancreatic cancer cells[J]. Biochem Pharmacol 2008; 75: 1035-1044
35. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways[J]. Oncologist 2008; 13: 289-298
36. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer[J]. Mol Cancer Ther 2003; 2: 1-7.
37. Juuti A, Louhimo J, Nordling S, et al. Cyclooxygenase- 2 expression correlates with poor prognosis in pancreatic cancer[J]. J Clin Pathol 2006; 59: 382-386
38. Albazaz R, Verbeke CS, Rahman SH, et al. Cyclooxygenase- 2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer[J]. Pancreatology 2005; 5: 361-369
39. Matsumoto G, Muta M, Tsuruta K, et al. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer[J]. Pancreatology 2007; 7: 167-173
40. Hermanova M, Trna J, Nenutil R, et al. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions[J]. Eur J Gastroenterol Hepatol 2008; 20: 732-739
41. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells[J]. Cancer Res 2006; 66: 2778-2784
42. Holcomb B, Yip Schneider M, Schmidt CM, et al. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy[J]. Pancreas 2008; 36: 225-235
43. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis[J]. Nature 2003; 425: 851-856
44. Nakashima H, Nakamura M, Yamaguchi H, et al. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer[J]. Cancer Res 2006; 66: 7041-7049
45. Sclabas GM, Fujioka S, Schmidt C, et al. NF-kappaB in pancreatic cancer[J]. Int J Gastrointest Cancer 2003; 33: 15-26.
46. Gong YL, Xu GM, Huang WD, et al. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer [J]. J Surg Oncol 2000; 73: 95-99
47. Schneiderhan W, Diaz F, Fundel M, et al. Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay[J]. J Cell Sci 2007; 120: 512-519
48. Juuti A, Lundin J, Nordling S, et al. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer[J]. Oncology 2006; 71: 61-68
49. Zhou DH, Trauzold A, Röder C, et al. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell[J]. Hepatobiliary Pancreat Dis Int 2008; 7: 201-209
50. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al, Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor[J]. Clin Cancer Res 2003; 9: 551-554
51. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore[J] Curr Opin Cell Biol 2001; 13: 534-540